Clinical efficacy of the anti-CD19 monoclonal antibody obexelimab has not yet been demonstrated (56), but chimeric antigen receptor T (CAR-T) cells engineered to recognize CD19 (antiCD19-CAR-T cell therapy) seems feasible, tolerable and highly effective in active systemic lupus erythematosus (57). Here, CD19 is linked to systemic lupus erythematosus.